Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Safety, Tolerability, Biodistribution, Dosimetry and Efficacy Study of 177Lu-DOTA-TLX591-CHO With Best Standard of Care in Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer

X
Trial Profile

A Phase 1 Safety, Tolerability, Biodistribution, Dosimetry and Efficacy Study of 177Lu-DOTA-TLX591-CHO With Best Standard of Care in Patients With PSMA Expressing Metastatic Castration-resistant Prostate Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium 177 DOTA rosopatamab (Primary) ; Antineoplastics
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Acronyms ProstACTSelect
  • Sponsors Telix Pharmaceuticals
  • Most Recent Events

    • 27 Jan 2024 Trial design presented at the 2024 Genitourinary Cancers Symposium
    • 22 Jan 2024 According to a Telix Pharmaceuticals media release, the company will presented data from this study at the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024) to be held in San Francisco, CA (US) from 25 - 27 January 2024.
    • 18 Oct 2023 Interim results were presented in a Telix Pharmaceuticals Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top